ABIGO Medical expands the Sorbact® product range with the novel Superabsorbent wound dressing

Infected wounds mean longer healing times, leading to unnecessary suffering for the patient and increased costs for the community. Sorbact® range of microbial binding dressings help preventing infections as well as managing already infected and hard-to-heal wounds. The new Sorbact® Superabsorbent dressing extends the use of Sorbact® to include high to excessive exuding wounds.

Sorbact® dressings prevent and treat wound infections by lowering the bioburden naturally, thereby improving clinical outcome and reducing patients suffering and healthcare costs. Using Sorbact® Technology, a modified wound contact surface more attractive for microorganisms to bind to than the wound bed, Sorbact® is irreversibly binding microorganisms, and removing them at dressing change.

The new Sorbact® Superabsorbent is the latest addition to the product range and the only microbial binding superabsorbent dressing available. It is intended for use in the management of wounds with high to excessive exudate levels, such as surgical wounds, traumatic wounds, pressure ulcers, diabetic ulcers and foot and leg ulcers. It combines the Sorbact® Technology with a superabsorbent core and a water repellent backing to prevent exudate strike through, available in the following sizes: 10x10cm, 10x20cm, 20x20cm and 20x30cm.

“Adding the Superabsorbent dressing is a response to customer and patient needs,” says Mattias Andrup, Medical Affairs Director at ABIGO Medical. “Customer reactions so far, have been very positive. It’s everything customers need from a superabsorbent dressing – and now with the Sorbact® Technology advantage.

Sorbact® Superabsorbent is launched initially in Europe, followed by other regions.

More about Sorbact®
Sorbact® binds to common wound microorganisms, such as Staphylococcus aureus, Streptococcus species, Escherichia coli, Pseudomonas aeruginosa and Candida albicans, and including MRSA¹ bacteria. No mechanisms of resistance to Sorbact® have been described.
Sorbact® is environmentally friendly, does not contain or release toxic agents, is non-allergenic, and can be used with children and during pregnancy.
Sorbact is available in a comprehensive range of dressing types and sizes and, through our partners and distributors, used in in more than 65 countries.

For more information on Sorbact® please visit www.abigo.com/products/wound-fungus/sorbact/

About ABIGO Medical
ABIGO Medical is a Swedish entrepreneurial pharmaceutical company that owns, develops, manufactures and markets pharmaceuticals and medical devices. ABIGO Medical has a wide range of non-prescription and prescription drugs, as well as a range of medical products in advanced wound management and ear, nose and throat (ENT) and in food for special medical purposes. The company was founded in 1989 by the current owners, brothers Jan G. Smith and Leif Smith, both still actively involved in the ABIGO management. ABIGO’s products are sold and used in over 60 countries, through its own sales organizations and partners. ABIGO’s turnover exceeds 200 million SEK annually with solid, continuous growth profitability, which is reinvested in research and development.

More information is available at www.abigo.com

Contact: Anders Elliot – Global Director Medical Device Division, anders.elliot@abigo.se, +46 31 748 49 50
Sorbact is a registered trademark of ABIGO Medical AB.

¹ Rönner U & A.C. et al. Adhesion of meticillin-resistant Staphylococcus aureus to DACC-coated dressings. J Wound Care,
vol 23, no 10, Oct. 2014.